(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 May 2022 (19.05.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/103966 A9

(51) International Patent Classification:
A61K 31/496 (2006.01) *A61P 9/04* (2006.01)
A61K 45/06 (2006.01) *A61P 7/04* (2006.01)
A61K 9/00 (2006.01) *A61P 9/10* (2006.01)

(21) International Application Number:
PCT/US2021/058988

(22) International Filing Date:
11 November 2021 (11.11.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/112,995	12 November 2020 (12.11.2020)	US
63/154,077	26 February 2021 (26.02.2021)	US
63/187,084	11 May 2021 (11.05.2021)	US
63/202,873	28 June 2021 (28.06.2021)	US
63/203,436	22 July 2021 (22.07.2021)	US

(71) Applicants: **AMGEN INC.** [US/US]; One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). **CYTOKINETICS, INC.** [US/US]; 280 East Grand Avenue, South San Francisco, California 94080 (US).

(72) Inventors: **HONARPOUR, Narimon**; c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). **MALIK, Fady**; c/o Cytokinetics, Inc., 280 East Grand Avenue, South San Francisco, California 94080 (US).

(74) Agent: **ZHONG, Qiwen** et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

(54) Title: METHODS OF TREATING HEART FAILURE BY ADMINISTERING OMECAMTIV MECARBIL




FIGURE 1A

(57) Abstract: Provided herein are methods of treating heart failure in patients exhibiting one or more additional features, comprising administering to the patient a therapeutically effective amount of omecamtiv mecarbil, or a hydrate, salt, or salt of a hydrate thereof.

[Continued on next page]

WO 2022/103966 A9

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

(48) **Date of publication of this corrected version:**
18 August 2022 (18.08.2022)

(15) **Information about Correction:**
see Notice of 18 August 2022 (18.08.2022)